Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D01QGX
|
||||
| Former ID |
DCL000873
|
||||
| Drug Name |
Lurasidone hydrochloride
|
||||
| Synonyms |
Lurasidone HCl; SM 13496; Lurasidone hydrochloride (USAN); MK-3756; SM-13496; SMP-13496; N-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinylmethyl)-1-cyclohexylmethyl)-2,3-bicyclo(2.2.1)heptanedicarboximide
|
||||
| Drug Type |
Small molecular drug
|
||||
| Company |
Sumitomo
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C28H36N4O2S
|
||||
| InChI |
InChI=1S/C28H36N4O2S/c33-27-24-18-9-10-19(15-18)25(24)28(34)32(27)17-21-6-2-1-5-20(21)16-30-11-13-31(14-12-30)26-22-7-3-4-8-23(22)35-29-26/h3-4,7-8,18-21,24-25H,1-2,5-6,9-17H2/t18-,19+,20-,21-,24+,25-/m0/s1
|
||||
| InChIKey |
PQXKDMSYBGKCJA-CVTJIBDQSA-N
|
||||
| CAS Number |
CAS 367514-87-2
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
16247346, 30417284, 47362895, 51026536, 57399659, 103068778, 103080863, 104253152, 117591937, 123051051, 134224709, 134339501, 135187871, 135692869, 136351322, 137892911, 160645972, 162011722, 162517092, 175265796, 175427100, 187051764, 223668806, 224768364, 226972568, 249821695, 249866658, 252110201, 252215721, 252448605
|
||||
| SuperDrug ATC ID |
N05AE05
|
||||
| Target and Pathway | |||||
| Target(s) | 5-hydroxytryptamine 2A receptor | Target Info | Modulator | [530859], [531351] | |
| D(2) dopamine receptor | Target Info | Modulator | [530859], [531351] | ||
| PANTHER Pathway | 5HT2 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| WikiPathways | Serotonin Receptor 2 and STAT3 Signaling | ||||
| Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||||
| SIDS Susceptibility Pathways | |||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| GPCRs, OtherWP666:Hypothetical Network for Drug Addiction | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| References | |||||
| Ref 530859 | Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010 Jul;334(1):171-81. | ||||
| Ref 531351 | Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. | ||||
| Ref 542486 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7461). | ||||
| Ref 551871 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.